Treatment of Secondary Erythema Nodosum When Oral Prednisone or Intralesional Corticosteroids Have Not Resolved the Nodules

Previous Treatment — Insufficient Response

This protocol is indicated when prior treatment with oral prednisone or intralesional triamcinolone acetonide — used for recalcitrant nodules — has failed to achieve resolution of tender erythematous nodules on the lower extremities. That unmet goal is the trigger for escalation to this next-line approach.

Treatment Target

The clinical goal is resolution of the tender erythematous nodules on the lower extremities. As nodules resolve, they characteristically transition from bright red to a yellow–brown or green-bluish discoloration.

Next-Line Approach — Partial Overview

When corticosteroid-based treatment has not controlled secondary erythema nodosum, the structured next-line protocol involves biologic therapy — specifically agents from the tumor necrosis factor-α (TNF-α) inhibitor class, used in patients with recalcitrant disease. The complete agent selection, sequencing, and dosing schedule are contained in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1007/s40257-021-00592-w

Tumor necrosis factor-α inhibitors such as etanercept, adalimumab, and infliximab have been used in patients with recalcitrant disease.

Erythema nodosum is generally self-limited and resolves within 1–6 weeks by turning from a bright red to a yellow–brown or green-bluish discoloration, resembling bruises.

View source ↗